Summary: A significant share of Americans have tried a GLP-1 drug like Ozempic for weight loss, even though the drug was never approved for that purpose. The latest large-scale research reveals real benefits alongside underappreciated risks that most off-label users likely never hear about.
The RAND Corporation found that roughly 12% of Americans have taken a GLP-1 medication specifically for weight loss. Another 14% say they are interested in trying one. Those are staggering numbers for a drug that was never approved for the thing millions of people are using it for.
What Ozempic Actually Is and How It Works
Ozempic is FDA-approved for one thing: treating Type 2 diabetes. Semaglutide, the active ingredient in Ozempic, belongs to a class of drugs called GLP-1 receptor agonists. These drugs mimic a natural hormone your gut releases after you eat. That hormone helps regulate blood sugar, controls hunger, and slows down digestion.
Wegovy, a different brand-name drug, also contains semaglutide. Wegovy has gone through the approval process for weight loss. Ozempic has not. Weight loss is technically a side effect of Ozempic, not its intended use.
A major reason people turn to Ozempic instead of Wegovy comes down to cost and access. Both drugs carry a list price of about $1,000 per month without insurance coverage. Some people have even started microdosing semaglutide, taking smaller doses than recommended, simply to stretch their supply and save money.
Why the Safety Question Is More Complicated Than It Seems
Most of what we know about GLP-1 drug safety comes from studies on people with diabetes, not people using these drugs purely for weight loss. That distinction matters more than you might think.
A landmark study published in Nature Medicine tracked 215,970 people with diabetes who started on GLP-1 receptor agonists. Researchers compared this group against multiple control groups, including a usual care group of over 1.2 million patients, mapping associations across 175 different health outcomes.
The Risks That Showed Up
The results were not uniformly reassuring. GLP-1RA use was associated with increased risk of gastrointestinal disorders compared to usual care. That aligns with what many users already report: nausea, vomiting, and digestive trouble.
But the study also flagged less obvious risks. Researchers found increased risk of drug-induced pancreatitis, a serious inflammation of the pancreas. There was also higher risk of hypotension and syncope, which means dangerously low blood pressure paired with fainting. Kidney problems showed up too, including nephrolithiasis and interstitial nephritis. The study even found increased risk of arthritic disorders.
The Benefits That Showed Up
The picture is not all negative. GLP-1RA use was linked to reduced risk of cardiometabolic disorders. That lines up with separate findings from Harvard Health, which notes that GLP-1 receptor agonists help prevent heart problems, one of the key complications of Type 2 diabetes. There were also reduced risks of neurocognitive disorders, including Alzheimer's disease and dementia.
The Nature Medicine study found additional benefits as well: lower risk of substance use and psychotic disorders, seizures, coagulation disorders, infectious illnesses, and several respiratory conditions.
GLP-1 drugs also carry a specific safety advantage over older diabetes medications. Because they increase insulin secretion in response to meals and lower blood sugar only when it is high, they carry less risk of dangerous hypoglycemia compared to insulin.
The Real-World Gap Between Evidence and Usage
Here is the problem. The Nature Medicine study population consisted exclusively of people with diabetes. We do not have equivalent large-scale data for healthy people taking semaglutide purely to shed pounds. The risk profile could look different in that group.
So where does that leave you? If you are considering Ozempic for weight loss, the honest answer is that you are stepping into a zone where the largest safety studies were done on a different population, for a different purpose. The drug shows real promise, but real risks too. Have you or someone you know tried a GLP-1 drug off-label, and did your doctor explain the gap in evidence before writing the prescription?
Comments